The level of tsh appeared favourable in maintaining bone mineral density in postmenopausal women

Endocrine Regulations

Volumn 44, Issue 1, 2010, Pages 9-15

  Baqi, L ^a   Payer, J ^a   Killinger, Z ^a   Susienkova, K ^b   Jackuliak, P ^a   Cierny, D ^a   Langer, P ^c  

^a University Hospital Ruzinov   (Slovakia)

^b Economics University   (Slovakia)

^c INSTITUTE OF EXPERIMENTAL ENDOCRINOLOGY   (Slovakia)

Author keywords

Bmd; Bone turnover markers; Free thyroxine; Osteoporosis; Postmenopausal women; Tsh

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; CALCIUM; CARBIMAZOLE; LEVOTHYROXINE; OSTEOCALCIN; THYROTROPIN; THYROXINE; ANTITHYROID AGENT; BIOLOGICAL MARKER; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; PEPTIDE;

ADULT; ARTICLE; BODY MASS; BONE DENSITY; BONE REMODELING; BONE TURNOVER; CALCIUM URINE LEVEL; CONTROLLED STUDY; FEMALE; FREE THYROXINE INDEX; GRAVES DISEASE; HUMAN; LONG TERM CARE; LUMBAR SPINE; MAJOR CLINICAL STUDY; OSTEOPOROSIS; POSTMENOPAUSE; THYROID CANCER; THYROID DISEASE; AGED; BLOOD; CASE CONTROL STUDY; CROSS-SECTIONAL STUDY; FEMUR; GOITER; LUMBAR VERTEBRA; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHOTON ABSORPTIOMETRY; RADIOGRAPHY; STATISTICAL MODEL; THYROID TUMOR; TIME; TREATMENT OUTCOME; URINE;

ABSORPTIOMETRY, PHOTON; AGED; ALKALINE PHOSPHATASE; ANTITHYROID AGENTS; BIOLOGICAL MARKERS; BONE DENSITY; CALCIUM; CARBIMAZOLE; CASE-CONTROL STUDIES; COLLAGEN TYPE I; CROSS-SECTIONAL STUDIES; FEMALE; FEMUR; GOITER; GRAVES DISEASE; HUMANS; LINEAR MODELS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOCALCIN; PEPTIDES; POSTMENOPAUSE; THYROID DISEASES; THYROID NEOPLASMS; THYROTROPIN; THYROXINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 77955895066     PISSN: 12100668     EISSN: 13360329     Source Type: Journal    
DOI: 10.4149/endo_2010_01_9     Document Type: Article

References (30)

1. Abe E, Marians RC, Yu W, Wu X-B, Ando T, Li Y, Iqbal J, Eldeiry L, Rajendren G, Blair HC, Davies T, Zaidi M: TSH is a negative regulator of skeletal remodeling. Cell 115, 151-162, 2003.doi:10.1016/S0092-8674(03)00771-2
2. Abe E, Sun L, Mechanick J, Iqbal J, Yamoah K, Baliram R, Arabi A, Moonga HS, Davies TF, Zaidi M: Bone loss in thyroid disease: Role of low TSH and high thyroid hormone. Ann NY Acad. Sci 116, 383-391, 2007. doi:10.1196/annals.1402.062
3. American Thyroid Association: Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 13, 3-126, 2003. doi:10.1089/105072503321086962
4. Basset JH, O'Shea PJ, Sriskantharajat S, Rabier B, Boyde A, Howell PG, Weiss RE, Roux JP, Malavat L, Clement-Lacroix P, Samarut J, Chassande O, William GR: Thyroid hormone excess rather than thyrotropin deficiency induces osteoporosis in hyperthyroidism. Mol Endocrinol 21, 1095-1107, 2007.doi:10.1210/me.2007-0033
5. Basset JH, Wiliams GR: Critical role of the hypothalamic-pituitary-thyroid axis in bone. Bone 43, 418-426, 2008.
6. Basset JH, Williams GR: The skeletal phenotype of TRα and TRβ mutant mice. Review. J Mol Endocrinol 42, 269-282, 2009.doi:10.1677/JME-08-0142
7. Diamond T, Nery L, Hales I: A therapeutic dilemma: Suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma. J Clin Endocrinol Metab 72, 1184-1188, 1990.doi:10.1210/jcem-72-6-1184
8. Grimnes G, Emaus N, Joakimsen RM, Figenschau Y, Jorde R: The relationship between serum TSH and bone mineral density in men and postmenopausal women: the Tromso study. Thyroid 18, 1147-1155, 2008. doi:10.1089/thy.2008.0158
9. Hamilton TE, Davis S, Onstad L, Kopecky KJ: Thyrotropin levels in a population with no clinical autoantibody, or ultrasonographic evidence of thyroid disease: implications for the diagnosis of subclinical hypothyroidism. J Clin Endocrinol Metab 98, 1224-1230, 2008.doi:10.1210/jc.2006-2300
10. Heemstra KA, Hamdy NAT, Romijn JA, Smith JWA: The effects of thyrotropin suppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma. Thyroid 16, 583-591, 2006doi:10.1089/thy.2006.16.583
11. Heijckman AC, Huiberts MSP, Geusens P, de Vries J, Menheere PPCA, Wolffenbuttel BHR: Hip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive L-thyroxine therapy for differentiated thyroid carcinoma. Eur J Endocrinol 153, 23-39, 2005. doi:10.1530/eje.1.01933
12. Hollowell JG, Staehling NW, Flanders WD, Gunter EW, Spencer CA, Braverman LE: Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 87, 489-499, 2002.doi:10.1210/jc.87.2.489
13. Kim DJ, Khang YH, Koh J-M, Shong YK, Kim GS: Low normal TSH levels are associated with low bone mineral density in healthy postmenopausal women. Clin Endocrinol 64, 86-90, 2006.doi:10.1111/j.1365-2265.2005.02422.x
14. Kung AWC, Yeung SSC: Prevention of bone loss induced by thyroxin suppressive therapy in postmenopausal women: The effect of calcium and calcitonin. J Clin Endocrinol Metab 81, 1232-1236, 1996.doi:10.1210/jc.81.3.1232
15. Martini G, Gennari L, De Paola V, Pilli T, Salvadori S, Merlotti D, Valleggi F, Campagna S, Franci B, Avanzati A, Nuti R, Pacini F: The effects of recombinant TSH on bone turnover markers and serum osteoprotegerin and RANKL levels. Thyroid 18, 455-460, 2008.doi:10.1089/thy.2007.0166
16. Mazziotti G. Sorvillo F, Piscopo M, Cioffi M, Pilla P, Biondi B, Iorio S, Giustina A, Amato G, Carella C: Recombinant human TSH modulates in vivo C-telopeptides of type-1collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma. J Bone Miner Res 20, 480-486, 2005.doi:10.1359/JBMR.041126
17. Morris MS: The association between serum thyroid-stimulating hormone in its reference range and bone status in postmenopausal American women. Bone 40, 1128-1134, 2007.doi:10.1016/j.bone.2006.12.001
18. Murphy E, Williams GR: The thyroid and the skeleton. Clin Endocrinol 61, 285-298, 2004. doi:10.1111/j.1365-2265.2004.02053.x
19. Panicker V, Wilson SG, Spector TD, Brown SJ, Falchi M, Richards JB, Surdulescu GI, Lim EM, Fletcher SJ, Walsh JP: Heritability of serum TSH, free T4 and free T3 concentrations: a study of a large UK twin cohort. Clin Endocrinol 68, 652-659, 2008.doi:10.1111/j.1365-2265.2007.03079.x
20. Quan ML, Pasieka JL, Rorstad O: Bone mineral density in well-differentiated thyroid cancer patients treated with suppressive thyroxine: a systematic overview of the literature. J Surg Oncology 79, 72-79, 2002.doi:10.1002/jso.10043
21. Sampath TK, Simic P, Sendak R, Draca N, Bowe AE, O'Brien S, Schiavi SC, McPherson JM, Vukicevic S: Thyroid-stimulating hormone restores bone volume, microarchitecture, and strength in aged ovariectomized rats. J Bone Miner Res 22, 849-859, 2007.doi:10.1359/jbmr.070302
22. Spencer CA, Takeuchi M, Kazarosyan M Current status and performance goals for serum thyrotropin assays. Clin Chem 42, 143-145, 1996.
23. Spencer CA, Hollowell JG, Kazarosyan M, Braverman LE: National health and nutrition examination survey III. Thyroid- stimulating hormone (TSH)/thyroperoxidase antibody relationship demonstrate that TSH upper reference limits may be skewed by occult thyroid dysfunction. J Clin Endocrinol Metab 92, 4236-4240, 2007. doi:10.1210/jc.2007-0287
24. Sun L, Vukicevic S, Baliram R, Yang G, Sendak R, McPherson J, Zhu L-L, Iqbal R, Latif R, Natrajan A, Arabi A, Yamoah K, Moonga BS, Gabet Y, Davies TF, Bab I, Abe E, Sampath K, Zaidi M: Intermittent recombinant TSH injections prevent ovariectomy-induced bone loss. Proc Natl Acad Sci 105, 4289-4294, 2008.doi:10.1073/pnas.0712395105
25. Surks MI, Hollowell JL: Age-specific distribution of serum thyrotropin and antithyroid antibodies in the U.S. population: Implications for the prevalence of subclinical hypothyroidism. J Clin Endocrinol Metab 91, 4575-4582, 2007.doi:10.1210/jc.2007-1499
26. Svare A, Nilsen TI, Bjoro T, Forsmo S, Schei B, Langhammer A: Hyperthyroid levels of TSH correlate with low bone mineral density: the HUNT 2 study. Eur J Endocrinol 16, 779-786, 2009. doi:10.1530/EJE-09-0139
27. Van der Deure WM, Uitterlinden AG, Hofman A, Rivadeneira F, Pols HAP, Peeters RP, Visser TJ: Effects of serum TSH and FT4 levels and the TSHR-Asp727Glu polymorphism on bone: the Rotterdam Study. Clin Endocrinol 68, 175-181, 2008.
28. Wartofsky L, Dickey R: The evidence for a narrower thyrotropin reference range is compelling. J Clin Endocrinol Metab 90, 5483-5488, 2005. doi:10.1210/jc.2005-0455
29. Williams GR: Actions of thyroid hormones in bone. Polish J Endocrinol 60, 380-388, 2009.
30. Zaidi M, Iqvbal J, Blair HC, Yallone A, Davies T, Sun L: Paradigm shift in the pathophysiology of postmenopausal and thyrotoxic osteoporosis. Mt Sinai J Med 76, 474-483, 2009. doi:10.1002/msj.20136